Page last updated: 2024-08-23

etoposide and Activated Protein C Resistance

etoposide has been researched along with Activated Protein C Resistance in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M	1
Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fassas, A; Fink, L; Mehta, P; Morris, C; Saghafifar, F; Siegel, E; Toor, A; Tricot, G; Whitfield, D; Zangari, M	1

Trials

1 trial(s) available for etoposide and Activated Protein C Resistance

Article	Year
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2002, Volume: 13, Issue:3 Topics: Activated Protein C Resistance; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Tests; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Factor V; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Life Tables; Male; Middle Aged; Multiple Myeloma; Risk; Thalidomide; Thrombophilia; Venous Thrombosis; Vincristine	2002

Article

Year

Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2002, Volume: 13, Issue:3

Topics: Activated Protein C Resistance; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Tests; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Factor V; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Life Tables; Male; Middle Aged; Multiple Myeloma; Risk; Thalidomide; Thrombophilia; Venous Thrombosis; Vincristine

2002

Other Studies

1 other study(ies) available for etoposide and Activated Protein C Resistance

Article	Year
Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:5 Topics: Activated Protein C Resistance; Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Doxorubicin; Etoposide; Factor V; Follow-Up Studies; Humans; Hyperhomocysteinemia; Multiple Myeloma; Prednisone; Pulmonary Embolism; Retrospective Studies; Thalidomide; Thrombophilia; Venous Thrombosis	2009

Article

Year

Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:5

Topics: Activated Protein C Resistance; Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Doxorubicin; Etoposide; Factor V; Follow-Up Studies; Humans; Hyperhomocysteinemia; Multiple Myeloma; Prednisone; Pulmonary Embolism; Retrospective Studies; Thalidomide; Thrombophilia; Venous Thrombosis

2009